Anzeige
Mehr »
Lynx Broker
Login
Montag, 21.10.2019 Börsentäglich über 12.000 News von 614 internationalen Medien

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2AN1Z ISIN: SE0000767188 Ticker-Symbol: 7AL 
Frankfurt
21.10.19
09:02 Uhr
1,124 Euro
+0,022
+2,00 %
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
ALLIGATOR BIOSCIENCE AB Chart 1 Jahr
5-Tage-Chart
ALLIGATOR BIOSCIENCE AB 5-Tage-Chart

Aktuelle News zur ALLIGATOR BIOSCIENCE Aktie

  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
Börsennews zur ALLIGATOR BIOSCIENCE Aktie und weiteren Hot Stocks erhalten
21.08.Alligator Bioscience, Biotheus Inc. Enter Antibody Agreement for Greater China1
20.08.Alligator Bioscience Signs Antibody Agreement for Greater China with Biotheus Inc.263LUND, Sweden, Aug. 20, 2019 /PRNewswire/ -- Alligator Bioscience (Nasdaq Stockholm: ATORX), today announces that a license agreement has been reached with Biotheus Inc. ("Biotheus"), a privately...
► Artikel lesen
31.07.Alligator Bioscience Regains Global Rights From Janssen to CD40 Agonistic Antibody, ADC-1013 (JNJ-64457107)96LUND, Sweden, July 31, 2019 /PRNewswire/ -- Alligator Bioscience (Nasdaq Stockholm: ATORX), today announces that it has regained exclusive, worldwide rights from Janssen Biotech Inc. to...
► Artikel lesen
11.07.Alligator Bioscience reports Q2 results1
11.07.Alligator Bioscience AB (publ) Interim Report January-June 201947- Competitive safety data for ADC-1013 STOCKHOLM, July 11, 2019 /PRNewswire/ -- Significant events April-June Janssen presented data from the clinical Phase I study with ADC-1013...
► Artikel lesen
18.06.Alligator Bioscience Submits Clinical Trial Application for ATOR-101744LUND, Sweden, June 18, 2019 /PRNewswire/ -- Alligator Bioscience (Nasdaq Stockholm: ATORX), a biotechnology company developing antibody-based pharmaceuticals for tumor-directed immunotherapy...
► Artikel lesen
16.05.Alligator Bioscience to Present the ATOR-1015 Phase I Study Outline at ASCO28STOCKHOLM, May 16, 2019 /PRNewswire/ -- Alligator Bioscience (Nasdaq Stockholm: ATORX) , today announces that the outline of the ongoing Phase I study with the bispecific drug candidate...
► Artikel lesen
16.05.Alligator Bioscience: ADC-1013 Clinical Phase I Data to be Presented at ASCO41LUND, Sweden, May 16, 2019 /PRNewswire/ -- Alligator Bioscience (Nasdaq Stockholm: ATORX), today announces that Janssen Biotech, Inc. (Janssen) will present data from a Phase I clinical study...
► Artikel lesen
17.04.The Nomination Committee's Proposal for the Annual Shareholders' Meeting in Alligator Bioscience AB (publ)22LUND, Sweden, April 17, 2019 /PRNewswire/ -- Alligator Bioscience (Nasdaq Stockholm: ATORX), today announces that the Nomination Committee in Alligator Bioscience has presented its proposal...
► Artikel lesen
17.04.Alligator Bioscience AB (publ) Interim Report January-March 201932First patient dosed in Phase I clinical study of ATOR-1015 STOCKHOLM, April 17, 2019 /PRNewswire/ -- Significant events January-March First patient dosed in Phase I clinical...
► Artikel lesen
10.04.Alligator Bioscience to Present New Preclinical Data on ATOR-1015 at PEGS Boston25LUND, Sweden, April 10, 2019 /PRNewswire/ -- Alligator Bioscience (Nasdaq Stockholm: ATORX), today announces that Chief Medical Officer Charlotte Russell, MD, PhD, will give an oral presentation...
► Artikel lesen
02.04.Alligator Bioscience: New Preclinical Data for ATOR-1144 Demonstrate Potential for Activation of Both the Innate and the Adaptive Immune System, as well as Direct Anti-tumor Effects31LUND, Sweden, April 2, 2019 /PRNewswire/ -- Alligator Bioscience (Nasdaq Stockholm: ATORX), today announce that new preclinical data on the drug candidate ATOR-1144 will be presented at the...
► Artikel lesen
22.03.Alligator Bioscience's Annual Report 2018 Published27LUND, Sweden, March 22, 2019 /PRNewswire/ -- Alligator Bioscience (Nasdaq Stockholm: ATORX), a biotechnology company developing antibody-based pharmaceuticals for tumor-directed immunotherapy...
► Artikel lesen
18.03.Alligator Bioscience: New Preclinical Data Demonstrate Strong Anti-tumor Effects for the 4-1BB Antibody ATOR-101723LUND, Sweden, March 18, 2019 /PRNewswire/ -- Alligator Bioscience (Nasdaq Stockholm: ATORX), today announce that they will present preclinical data for the drug candidate ATOR-1017 at the...
► Artikel lesen
07.03.Alligator Bioscience: First Patient Dosed in Phase I study of ATOR-1015132Dose-escalation study commences with first-in-class bispecific CTLA-4 antibody LUND, Sweden, March 7, 2019 /PRNewswire/ -- Alligator Bioscience (Nasdaq Stockholm: ATORX) today announces...
► Artikel lesen
14.02.Alligator Bioscience AB Year-end Report 201826STOCKHOLM, Feb. 14, 2019 /PRNewswire/ -- Significant events October-December The Swedish MPA (Medical Products Agency) approved start of Phase I clinical trial of ATOR-1015. New...
► Artikel lesen
12.02.Alligator Bioscience to Host Conference Call to Provide Year-end Report 2018 Business Update20STOCKHOLM, Feb. 12, 2019 /PRNewswire/ -- Alligator Bioscience (Nasdaq Stockholm: ATORX) - On 14 February 2019, at 08:00 a.m. CET, Alligator Bioscience will publish its report for the...
► Artikel lesen
29.01.Alligator Bioscience Publishes Clinical Phase I Data for ADC-1013 in the International Journal of Cancer 29First-in-human study with intratumoral administration of a CD40 agonistic antibody, ADC-1013, in advanced solid malignancies LUND, Sweden, Jan. 29, 2019 /PRNewswire/ -- Alligator Bioscience...
► Artikel lesen
07.01.Alligator Bioscience Launches RUBY, a Novel Concept in Bispecific Antibody Formats43Priority filling submitted RUBY bispecific concept has been developed to achieve an outstanding stability, manufacturability and shorter development timelines LUND, Sweden, Jan....
► Artikel lesen
11.12.18Alligator Bioscience Starts Clinical Phase I Study With ATOR-101520A first-in-class bispecific CTLA-4 antibody LUND, Sweden, Dec. 11, 2018 /PRNewswire/ -- Alligator Bioscience AB (Nasdaq Stockholm: ATORX) today announces that regulatory approvals...
► Artikel lesen
Seite:  Weiter >>
25 Nachrichten in den letzten 12 Monaten

Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1